发明授权
US08541553B2 Antibodies specific for the melanoma-associated endogenous retrovirus (MERV) envelope glycoprotein
失效
针对黑素瘤相关内源性逆转录病毒(MERV)包膜糖蛋白特异的抗体
- 专利标题: Antibodies specific for the melanoma-associated endogenous retrovirus (MERV) envelope glycoprotein
- 专利标题(中): 针对黑素瘤相关内源性逆转录病毒(MERV)包膜糖蛋白特异的抗体
-
申请号: US12601780申请日: 2008-05-23
-
公开(公告)号: US08541553B2公开(公告)日: 2013-09-24
- 发明人: Johannes Humer , Bernd Mayer , Thomas Muster , Andrea Waltenberger
- 申请人: Johannes Humer , Bernd Mayer , Thomas Muster , Andrea Waltenberger
- 申请人地址: CH Glattpark (Opfikon)
- 专利权人: Baxter Healthcare SA
- 当前专利权人: Baxter Healthcare SA
- 当前专利权人地址: CH Glattpark (Opfikon)
- 代理机构: Loza & Loza, LLP
- 代理商 Michael Fedrick
- 优先权: ATA830/2007 20070524; ATA160/2008 20080201
- 国际申请: PCT/EP2008/056359 WO 20080523
- 国际公布: WO2008/142157 WO 20081127
- 主分类号: C07K16/00
- IPC分类号: C07K16/00 ; C12N5/07 ; A61K39/42 ; A61K39/21
摘要:
The present invention provides antibodies, or fragments thereof, for isolating and/or identifying epitopes of an endogenous retrovirus, preferably of a melanoma associated endogenous retrovirus, and hybridoma cells producing said antibodies. The antibodies are useful especially for the treatment and diagnosis of cancer. Further, the present application covers diagnostic kits for the detection of cancer cells, especially of melanoma cells and methods for cancer diagnosis using said antibodies.
公开/授权文献
- US20100136518A1 ANTIBODIES USEFUL FOR THERAPY AND DIAGNOSIS OF CANCER 公开/授权日:2010-06-03
信息查询